Royalty Monetization$230 Million
HCR purchased royalties on sales of GSK’s QS-21 containing vaccines, including Shingrix. Shingrix is a non-live, recombinant subunit vaccine for the prevention of shingles (herpes zoster) in adults aged 50 years and older.
HCR purchased the royalty interest from Agenus Inc. Agenus monetized its royalty on sales of the GSK QS-21 vaccines in order to strengthen its balance sheet and help fund the development of its pipeline of immuno-oncology programs.
Note: This transaction also appears in the Corporate Financing section under Agenus, Inc.